ATE42679T1 - Verfahren zur isolierung und reinigung des hepatitis-b-oberflaechen-antigens. - Google Patents

Verfahren zur isolierung und reinigung des hepatitis-b-oberflaechen-antigens.

Info

Publication number
ATE42679T1
ATE42679T1 AT86870069T AT86870069T ATE42679T1 AT E42679 T1 ATE42679 T1 AT E42679T1 AT 86870069 T AT86870069 T AT 86870069T AT 86870069 T AT86870069 T AT 86870069T AT E42679 T1 ATE42679 T1 AT E42679T1
Authority
AT
Austria
Prior art keywords
hepatitis
isolation
purification
procedure
surface antigen
Prior art date
Application number
AT86870069T
Other languages
English (en)
Inventor
Wijnendaele Frans Van
Guy Simonet
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Application granted granted Critical
Publication of ATE42679T1 publication Critical patent/ATE42679T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Insulated Conductors (AREA)
  • Magnetic Heads (AREA)
  • Adornments (AREA)
AT86870069T 1985-05-30 1986-05-21 Verfahren zur isolierung und reinigung des hepatitis-b-oberflaechen-antigens. ATE42679T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/739,415 US4649192A (en) 1985-05-30 1985-05-30 Method for the isolation and purification of hepatitis B surface antigen using polysorbate
EP86870069A EP0204680B1 (de) 1985-05-30 1986-05-21 Verfahren zur Isolierung und Reinigung des Hepatitis-B-Oberflächen-Antigens

Publications (1)

Publication Number Publication Date
ATE42679T1 true ATE42679T1 (de) 1989-05-15

Family

ID=24972199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86870069T ATE42679T1 (de) 1985-05-30 1986-05-21 Verfahren zur isolierung und reinigung des hepatitis-b-oberflaechen-antigens.

Country Status (12)

Country Link
US (1) US4649192A (de)
EP (1) EP0204680B1 (de)
JP (1) JPS61280438A (de)
AT (1) ATE42679T1 (de)
AU (1) AU589331B2 (de)
CA (1) CA1259922A (de)
DE (1) DE3663108D1 (de)
DK (1) DK247586A (de)
ES (1) ES8706444A1 (de)
GR (1) GR861357B (de)
PT (1) PT82644B (de)
ZA (1) ZA863935B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
WO1987001128A1 (en) * 1985-08-15 1987-02-26 Amgen Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells
US4742158A (en) * 1986-04-25 1988-05-03 Merck & Co., Inc. Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
RU1389060C (ru) * 1986-08-13 1993-06-30 Институт иммунологии Способ получени рекомбинатной вакцины к гепатиту В
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
CA1341074C (en) 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5030720A (en) * 1988-09-01 1991-07-09 Merck & Co., Inc. Pres2+S hepatitis B vaccine derived from plasma
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
JPH06503231A (ja) * 1991-09-18 1994-04-14 アムジエン・インコーポレーテツド 胆汁酸塩を含有するｂ型肝炎ワクチン製剤
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
US20040057969A1 (en) * 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
EP1909830B1 (de) * 2005-08-02 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
JP2009536958A (ja) 2006-05-11 2009-10-22 ベクトン・ディキンソン・アンド・カンパニー 細胞からのタンパク質抽出方法
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2303562A1 (fr) * 1975-03-14 1976-10-08 Community Blood Council Greate Nouvelle preparation d'antigene utilisable comme vaccin
US4113712A (en) * 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
US4102996A (en) * 1977-04-20 1978-07-25 Merck & Co., Inc. Method of preparing hepatitis B core antigen
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4234564A (en) * 1977-12-19 1980-11-18 Merck & Co., Inc. Hepatitis B core antigen composition
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
JPH0625069B2 (ja) * 1981-01-29 1994-04-06 ブリティッシュ・テクノロジー・グループ・リミテッド Ｂ型肝炎ワクチン製造方法
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
EP0135435A3 (de) * 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenisches HBsAg aus transformierter Hefe stammend
JPS60197629A (ja) * 1984-03-16 1985-10-07 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法

Also Published As

Publication number Publication date
JPS61280438A (ja) 1986-12-11
DK247586D0 (da) 1986-05-27
CA1259922A (en) 1989-09-26
ES8706444A1 (es) 1987-07-01
EP0204680B1 (de) 1989-05-03
AU5790686A (en) 1986-12-04
ES555442A0 (es) 1987-07-01
PT82644B (pt) 1988-03-03
PT82644A (en) 1986-06-01
DK247586A (da) 1986-12-01
ZA863935B (en) 1987-03-25
DE3663108D1 (en) 1989-06-08
US4649192A (en) 1987-03-10
EP0204680A2 (de) 1986-12-10
JPH0450294B2 (de) 1992-08-13
GR861357B (en) 1986-09-25
EP0204680A3 (en) 1987-01-14
AU589331B2 (en) 1989-10-05

Similar Documents

Publication Publication Date Title
ATE42679T1 (de) Verfahren zur isolierung und reinigung des hepatitis-b-oberflaechen-antigens.
DE3477139D1 (en) Hepatitis b vaccine and method for its preparation
ES2104359T3 (es) Silice modificada superficialmente.
DE69534872D1 (de) Gereinigte primate clta-8 antigene und verwandte reagenzien
DE69840334D1 (de) Puffern zur stabilizierung von hcv antigenen
ATE45682T1 (de) Eisenhaltiger katalysator zur verringerung des stickoxidgehalts von verbrennungsabgasen.
ATE139986T1 (de) Verfahren und zusammensetzung zur inhibierung der ablagerung von silika und silikaten
AT382089B (de) Verfahren und einrichtung zur reinigung von mit staeuben und schadgasen verunreinigten abgasen
DE69021496D1 (de) Integrierter Prozess zur Produktion von Diisopropylether und Benzin.
AU1493995A (en) Monoclonal antibody
UA32516C2 (uk) Спосіб очищення газів з використанням піноутворюючого реактиву та установка для його здійснення
EA199800332A1 (ru) Способ очистки алкоксилированных жиров
ATE33842T1 (de) Immuninterferon und verfahren zu seiner reinigung.
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
GB2064322B (en) Process for purifying particles of biological origin particularly the surface antigen of the virus of hepatitis b (aghbs)
AU678404B2 (en) Process for the purification and concentration of rubella virus
KR970061272A (ko) B형 간염 표면 항원의 정제방법

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties